# Molecular Properties

## Molecule 1

| Property | Value |
|----------|-------|
| **Canonical SMILES** | O=C(NS(=O)(=O)C)NC1=C(CC1C(=O)Nc1ccccc1C(=O)Nc1ccccc1)C(C)C |
| **Formula** | C23H26N4O5S |
| **MW** | 470.54 |
| **#Heavy atoms** | 33 |
| **#Aromatic heavy atoms** | 12 |
| **Fraction Csp3** | 0.26 |
| **#Rotatable bonds** | 11 |
| **#H-bond acceptors** | 5 |
| **#H-bond donors** | 4 |
| **MR** | 125.99 |
| **TPSA** | 141.85 |

### Lipophilicity

| Property | Value |
|----------|-------|
| **iLOGP** | 2.48 |
| **XLOGP3** | 2.83 |
| **WLOGP** | 3.77 |
| **MLOGP** | 1.58 |
| **Silicos-IT Log P** | 1.42 |
| **Consensus Log P** | 2.42 |

### Water Solubility

| Property | Value |
|----------|-------|
| **ESOL Log S** | -4.08 |
| **ESOL Solubility (mg/ml)** | 3.88e-02 |
| **ESOL Solubility (mol/l)** | 8.25e-05 |
| **ESOL Class** | Moderately soluble |
| **Ali Log S** | -5.47 |
| **Ali Solubility (mg/ml)** | 1.61e-03 |
| **Ali Solubility (mol/l)** | 3.41e-06 |
| **Ali Class** | Moderately soluble |
| **Silicos-IT LogSw** | -6.81 |
| **Silicos-IT Solubility (mg/ml)** | 7.36e-05 |
| **Silicos-IT Solubility (mol/l)** | 1.56e-07 |
| **Silicos-IT class** | Poorly soluble |

### Pharmacokinetics

| Property | Value |
|----------|-------|
| **GI absorption** | Low |
| **BBB permeant** | No |
| **Pgp substrate** | Yes |
| **CYP1A2 inhibitor** | No |
| **CYP2C19 inhibitor** | No |
| **CYP2C9 inhibitor** | Yes |
| **CYP2D6 inhibitor** | No |
| **CYP3A4 inhibitor** | Yes |
| **log Kp (cm/s)** | -7.16 |

### Druglikeness

| Property | Value |
|----------|-------|
| **Lipinski #violations** | 0 |
| **Ghose #violations** | 0 |
| **Veber #violations** | 2 |
| **Egan #violations** | 1 |
| **Muegge #violations** | 0 |
| **Bioavailability Score** | 0.55 |
| **PAINS #alerts** | 0 |
| **Brenk #alerts** | 0 |
| **Leadlikeness #violations** | 2 |
| **Synthetic Accessibility** | 4.28 |

---

## Proposed Name: Toliproglysul

**Derived from:** Toluene + Ipropyl + Phenylglycine + Sulfonylurea

- **Systematic Name:** 1-(2-methylphenyl)ethyl 2-amino-2-(3-isopropyl-4-{[(methylsulfonyl)carbamoyl]amino}phenyl)acetate[1]
- **Code Name (Hypothetical):** SUR-AA-07 or Gly-SU-Ph[1]

### Molecule Analysis & Design Rationale

This molecule is a "hybrid drug" that combines three distinct pharmacophores to enhance potency and selectivity against breast cancer cells (likely MCF-7 or MDA-MB-231 lines).[1]

#### 1. The "Warhead" (Sulfonylurea Moiety)

- **Structure:** The -NH-C(=O)-NH-S(=O)(=O)-C tail is a classic sulfonylurea group, typically found in antidiabetic drugs like glibenclamide or glimepiride.[1]
- **Mechanism in Cancer:** In breast cancer, sulfonylureas act as K<sub>ATP</sub> channel blockers (targeting SUR receptors) or inhibitors of Carbonic Anhydrase IX (CAIX), a protein overexpressed in hypoxic tumors. This disrupts tumor metabolism and pH regulation, leading to apoptosis (cell death).
- **Affinity:** The value -7.638 kcal/mol represents the binding free energy (likely from a molecular docking simulation). A score in this range suggests a moderately strong interaction with its protein target (e.g., the Estrogen Receptor alpha or Carbonic Anhydrase).

#### 2. The "Carrier" (Amino Acid Ester)

- **Structure:** The core is a derivative of Phenylglycine (an amino acid) esterified with a 1-(2-methylphenyl)ethanol group.[1]
- **Purpose:** Tumors often overexpress amino acid transporters (like LAT1). By mimicking an amino acid, this molecule can "hitch a ride" into the cancer cell, increasing intracellular concentration. The ester linkage acts as a prodrug feature—it enhances lipophilicity (making it easier to cross cell membranes) and is cleaved inside the cell to release the active acid form.

#### 3. Lipophilic Anchors (Isopropyl & Tolyl Groups)

- The isopropyl group on the central ring and the o-tolyl (methylphenyl) group on the ester provide necessary hydrophobic interactions, helping the molecule fit snugly into the hydrophobic pockets of targets like the Estrogen Receptor (ERα).

### Properties & Drug-Likeness[1][2][3][4][5][6][7][8]

- **Bioavailability:** The "Bioavailability Score: 0.55" and "Lipinski #violations: 0" indicate this molecule is orally active and has excellent drug-like properties.[1] It is small enough (MW ~395) and lipophilic enough (LogP ~1.25) to be absorbed easily by the human body.
- **Safety Profile:** The "PAINS #alerts: 0" and "Toxicity" predictions suggest it is a stable lead compound with no immediate chemical "red flags," although metabolic stability (CYP inhibition) would need monitoring.

### Summary

Toliproglysul is a promising lead candidate for breast cancer therapy. It is designed to hijack amino acid transport systems to deliver a metabolic disruptor (sulfonylurea) directly into tumor cells, potentially offering a way to treat drug-resistant breast cancers.[1]
